The Patent Finder

Terms ending in 2034

Astellas US LLC

Every in-force patent on Astellas US LLC's record whose computed term ends in 2034, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 9,808,530Composition of Tiacumicin Compounds
In force
 · High confidence
Merck Sharp & Dohme LLCIn forceHigh confidence
US 11,273,171Methods for Treating or Preventing Ophthalmological Conditions
In force
 · High confidence
Astellas US LLCIn forceHigh confidence
US 11,491,176Methods for Treating or Preventing Ophthalmological Conditions
In force
 · High confidence
Astellas US LLCIn forceHigh confidence
US 12,016,875Methods for Treating or Preventing Ophthalmological Conditions
In force
 · High confidence
Astellas US LLCIn forceHigh confidence
4 of 4 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Astellas US LLC.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited